HIMS:NYE-Hims Hers Health Inc (USD)

COMMON STOCK | Household & Personal Products |

Last Closing

USD 27.23

Change

0.00 (0.00)%

Market Cap

USD 6.47B

Volume

0.02B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-12 )

Largest Industry Peers for Household & Personal Products

Symbol Name Price(Change) Market Cap
UL Unilever PLC ADR

+0.33 (+0.53%)

USD 146.70B
KMB Kimberly-Clark Corporation

+2.80 (+2.00%)

USD 46.31B
CHD Church & Dwight Company Inc

+1.23 (+1.18%)

USD 26.84B
CLX The Clorox Company

-0.50 (-0.35%)

USD 17.42B
COTY Coty Inc

-0.01 (-0.19%)

USD 4.80B
ELF ELF Beauty Inc

-0.15 (-0.28%)

USD 3.85B
SPB Spectrum Brands Holdings Inc

-0.28 (-0.45%)

USD 1.62B
EPC Edgewell Personal Care Co

+0.24 (+0.81%)

USD 1.44B
PZC PIMCO California Municipal Inc..

+0.02 (+0.33%)

USD 0.63B
YSG Yatsen Holding

+0.16 (+4.55%)

USD 0.32B

ETFs Containing HIMS

EDOC:LSE Global X Telemedicine & D.. 6.56 % 0.00 %

+0.30 (+2.26%)

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 6.56 % 0.00 %

+0.17 (+2.26%)

USD 0.33M
EDOC Global X Telemedicine & D.. 5.38 % 0.00 %

N/A

USD 0.03B
EDOC:AU 4.99 % 0.00 %

N/A

N/A
DDOC:F Global X Telemedicine & D.. 4.59 % 0.00 %

+0.11 (+2.26%)

N/A
EDOC:SW Global X Telemedicine & D.. 4.40 % 0.00 %

+0.22 (+2.26%)

N/A
FCUS Pinnacle Focused Opportun.. 4.30 % 0.00 %

+0.09 (+2.26%)

USD 0.04B
FDOC:LSE 3.42 % 0.00 %

N/A

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.94 % 0.00 %

+2.97 (+2.26%)

USD 0.19B
RTWP:LSE Legal & General UCITS ETF.. 0.94 % 0.00 %

+150.50 (+2.26%)

USD 0.19B
RSSL:AU Global X Russell 2000 Etf 0.82 % 0.00 %

+0.18 (+2.26%)

N/A
IDP6:SW iShares S&P SmallCap 600 .. 0.65 % 0.00 %

+2.35 (+2.26%)

USD 2.48B
ZSML-F:CA BMO S&P US Small Cap Inde.. 0.65 % 0.00 %

N/A

CAD 5.46M
ZSML-U:CA BMO S&P US Small Cap Inde.. 0.65 % 0.00 %

N/A

N/A
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

+0.92 (+2.26%)

USD 4.13B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

+1.74 (+2.26%)

USD 4.13B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.33 % 0.00 %

+0.06 (+2.26%)

USD 2.91B
R2US:SW SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

+2.29 (+2.26%)

USD 4.18B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

+0.53 (+2.26%)

N/A
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+0.70 (+2.26%)

USD 0.11B
IBUY Amplify Online Retail ETF 0.00 % 0.65 %

+0.30 (+2.26%)

USD 0.16B
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

+0.89 (+2.26%)

USD 0.43B
JSML Janus Henderson Small Cap.. 0.00 % 0.50 %

+0.75 (+2.26%)

USD 0.17B
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

+0.52 (+2.26%)

USD 0.70B
SAA ProShares Ultra SmallCap6.. 0.00 % 0.95 %

+0.47 (+2.26%)

USD 0.03B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

+2.00 (+2.26%)

USD 0.94B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

+0.92 (+2.26%)

USD 11.00B
XHS SPDR® S&P Health Care Se.. 0.00 % 0.35 %

+0.75 (+2.26%)

USD 0.08B
ISP6:LSE iShares III Public Limite.. 0.00 % 0.00 %

+156.00 (+2.26%)

USD 2.76B
ZSML:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

+0.44 (+2.26%)

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

+0.26 (+2.26%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Household & Personal Products) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.61% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.61% 100% F 95% A
Trailing 12 Months  
Capital Gain 95.06% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.06% 100% F 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 52.02% 94% A 95% A
Dividend Return 52.02% 76% C+ 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.02% 6% D- 8% B-
Risk Adjusted Return 52.54% 76% C+ 66% D+
Market Capitalization 6.47B 69% C- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.